Skip to content
BIO Coffee Chat: Guiding patients through Part D open enrollment
Medicare’s 2026 Open Enrollment period for Part D plans began on Oct. 15 ...
Read More
BIO on the American Road: Indiana, a production powerhouse, is still expanding
At a time when the biopharma industry is seeking to increase U.S. manufacturing, ...
Read More
Ahead of BIO IP Conference, research highlights why biotech needs strong patents
Venture capital funding for life sciences startups plummeted after legal changes weakened the ...
Read More
PACE: Downstream effects of IRA on patients
Three years after the passage of the Inflation Reduction Act (IRA), patient advocates ...
Read More
PACE panel urges incentives for exciting new GTT drugs
Luke Rosen had hoped a new treatment would slow the progression of his ...
Read More
PACE: How 340B outgrew its goal and stopped helping patients
The 340B program, in recent decades, has shown how the best laid plans ...
Read More
EDITORS' CHOICE
A conversation with Fritz Bittenbender, new BIO Board Chair
The exciting new developments we’re seeing in biotechnology must be supported by equally innovative policy, according to Fritz Bittenbender, the new Chair of the Board ...
Read More
LATEST NEWS
Federal Policy
BIO Coffee Chat: Guiding patients through Part D open enrollment
Medicare’s 2026 Open Enrollment period for Part D plans began on Oct. 15 and runs through Dec. 7. “As patient advocates have seen year after ...
BIO Events
BIO on the American Road: Indiana, a production powerhouse, is still expanding
At a time when the biopharma industry is seeking to increase U.S. manufacturing, Indiana is in the vanguard—and still expanding. During a Nov. 11 BIO ...
BIO Events
Ahead of BIO IP Conference, research highlights why biotech needs strong patents
Venture capital funding for life sciences startups plummeted after legal changes weakened the patent system, according to new research that confirms the close relationship between ...
BIO Events
PACE: Downstream effects of IRA on patients
Three years after the passage of the Inflation Reduction Act (IRA), patient advocates and the biotech industry are working to navigate downstream negative impacts on ...
Federal Policy
PACE panel urges incentives for exciting new GTT drugs
Luke Rosen had hoped a new treatment would slow the progression of his daughter’s KIF1A Associated Neurological Disorder (KAND), but was amazed to see an ...
HEALTH
Welcome, John F. Crowley!
Get to know John F. Crowley, the new President and CEO of the Biotechnology Innovation Organization (BIO), in our exclusive interview.
Federal Policy
State Policy
BIO PACE 2025: Patients need to ensure state policies enable access to medicine
With Medicaid cuts expected, vaccine hesitancy getting politicized, and the continued challenge of Prescription Drug Affordability Boards (PDABs), state legislatures ...
Read More
International
Bio's View
Putting Americans First: Importing European prices means importing European systems and values
European countries don’t just pull prices for medicines out of thin air. The prices that those governments set are based ...
Read More
